TGTX expects BRIUMVI U.S. net product revenue of around $40 million for Q4 and $89 million for FY23.

The company projects a year-end 2023 cash position of about $215 million.

Outlook: TGTX sees BRIUMVI U.S. net product revenue of $41 million-$46 million in Q1 and $220 million-$260 million for FY24.

The company expects to achieve operating expenses of about $250 million in FY24.

In FY24, TGTX plans to start clinical development of subcutaneous BRIUMVI and commence a trial evaluating BRIUMVI in additional autoimmune diseases apart from Multiple Sclerosis (MS).

Also, the company aims to start a trial for evaluating azer-cel in autoimmune disease and present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences this year.

Price Action: TGTX shares are up 10.52% at $23.22 premarket on the last check Wednesday.